Detail akcie Edgewise Therap Rg online

Business Summary: Edgewise Therapeutics, Inc. is a muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company’s lead product candidate, sevasemten (EDG-5506), is an orally administered skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. Its EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, which is in Phase II clinical development. The Company is using its proprietary drug discovery platform to develop a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address a broad array of serious muscle disorders. Its platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Edgewise Therapeutics Inc revenues was not reported. Net loss increased 25% to $117.6M. Higher net loss reflects Biotechnology & Medical Research segment loss increase of 20% to $135.4M, United States segment loss increase of 72% to $135.4M. Basic Earnings per Share excluding Extraordinary Items decreased from -$1.03 to -$1.16.